Welcome to the future of biopharmaceutical R&D and Manufacturing. Our advanced metabolic-strain engineering and purification platforms enable revolutionary efficiencies in biopharmaceutical discovery and manufacturing.
SoluPro™, our all-in-one protein expression platform, produces complex proteins ranging from full-length antibodies to insulin using the simplest, best studied, and least expensive organism, E. coli.
AbSci Advantages
Next-generation E. Coli chassis, SoluPro™ produced soluble, disulfide bonded, active protein without refolding
“First-of-its-kind” workflow partners a high-titer cell line in 12 weeks that produces high-quality product
Rapid cell line development and elimination of viral clearance for gene to GMP drug substance in 6-9 months
Up to 75% reduction in drug substance costs due to high titers and reduced number of production runs
Ultra-High Yield Streamlined Protein Production
OUR TECHNOLOGY
Two key innovations form the foundation of our SoluPro™ protein expression platform: a carefully engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables precision control over protein production rates. AbSci’s unprecedented approach and proprietary understanding of protein folding enables SoluPure a chromatography-free purification method that removes downstream processing bottlenecks.
This scalable downstream purification technique utilizes existing standard to remove host-cell proteins and eliminate downstream chromatography steps. Together, SoluPure™ and SoluPro™ introduce numerous efficiencies throughout biologic discovery and manufacturing by providing rapid access to therapeutic candidates, simplifying downstream purification, and achieving fermentation titers that can be measured in tens of grams per liter.
Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space. SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.
AbSci takes advantage of the simplicity of E. Coli to assemble and screen large pools of generic diversity in parallel. Using high-throughput and workflows, the ideal production strain can be identified in 3 months or less. Rapid optimization of a high-titer producing strains enables pharmaceutical and biotech partners to go from gene to GMP drug substance in less than 9 months and eliminates the need for viral clearance, which results in dramatic time savings compared to CHO.
At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, reducing the number of production campaigns or scale of bioreactor required to produce sufficient drug substances. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.
SoluPro™, AbSci’s next-generation E. Coli expression platform, generates diverse protein products at unparalleled yields compared to current manufacturing processes. Our technologies decrease COG’s, reduce production times, and significantly increase plant capacity.
AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.
AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.
Accelerate the drug discovery process using AbSci’s all-in-one protein expression platform, SoluPro™. The optimization process enables rapid expression of soluble, complex proteins in high yields, and puts the focus on screening lead candidates instead of producing them.
PARTNERSHIPS
27
Molecules
12
Partners
PARTNERSHIPS
Absci collaborates with leading pharmaceutical companies to enable step-changes in productivity to their bio-pharmaceutical R&D and manufacturing.
AbSci is supported by a syndicate of experienced investors:
“People in the industry have been talking about folding protein in E. coli for years. Before it was just theoretically possible, but the SoluPro™ Platform now makes it technically possible to fold full-length antibodies and proteins in E. coli.”
Fred Larimore, PhD, Former Research Fellow at Eli Lilly
ABOUT US
We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry.
AbSci scientists are iconoclasts, defying established industry practices, resolute in a shared conviction that the status quo for biomanufacturing is obsolete. We attract passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.
Our Scientific Advisory Board and Board of Directors are comprised of world-class scientists who bring decades of experience leading and igniting the biotech industry in all facets of drug discovery and biomanufacturing.
Leadership Team
Sean McClain
Founder, CEO & Director
Biotech Innovator & Entrepreneur. Led the invention of AbSci’s many patented technologies.
Greg Schiffman, CPA
CFO
34+ years of experience. Working in senior finance roles at top-tier biotech companies including Dendreon (CFO), Affymetrix (CFO), and Applied Biosystems (VP, finance)
Matthew Weinstock, Ph.D.
CTO
Dedicated biotech professional with experience in drug discovery, strain engineering, and commercialization of synthetic biology technologies.
Lare McClure, Ph.D., JD
General Counsel
20+ years of experience as a registered patent attorney and Ph.D. chemist with experience practicing intellectual property law.Previously Partner at DLA Piper.
Board of Directors
Zachariah Jonasson, Ph.D.
Chairman, Managing Partner PVP
25 Years Experience
Sean McClain
Founder, CEO & Director
Biotech Innovator & Entrepreneur
Gustavo Mahler, Ph.D.
CEO, AGC Biologics
20 Years Experience
V. Bryan Lawlis, Ph.D.
Independent Consultant
37 Years Experience
Ivana Magovcevic-Liebisch, Ph.D
President & CEO, Vigil Neuroscience
22 Years Experience
Andy Pihl
COO, AbSci
34 Years Experience
Karen McGinnis, CPA
Chief Accounting Officer, Illumina
31 Years Experience
Eli Casdin
CIO, Casdin Capital
Amrit Nagpal
Managing Director at Redmile Group
“AbSci reminds me of Genentech in the early 80’s, they’ve taken on some really hard problems to explain and there’s no fear around solving these key industry issues.”
V. Bryan Lawlis, PhD, Former VP of Process Science at Genentech
CAREERS
Join the Team | Change an Industry
At AbSci, we defy established protein expression conventions and continually invent new technologies and approaches which introduce efficiencies and cost savings to the biotech industry. We are looking for original thinkers, accomplished and energetic scientists who have the imagination to join us and re-define what’s possible.
